HC Wainwright Lowers Femasys (NASDAQ:FEMY) Price Target to $12.00

Femasys (NASDAQ:FEMY) had its price target dropped by analysts at HC Wainwright from $15.00 to $12.00 in a note issued to investors on Friday,Benzinga reports. The brokerage currently has a “buy” rating on the stock.

Femasys Stock Down 7.8 %

Femasys stock opened at $1.06 on Friday. The business’s 50-day simple moving average is $1.29 and its two-hundred day simple moving average is $1.23. The company has a debt-to-equity ratio of 0.86, a quick ratio of 3.26 and a current ratio of 3.94. The company has a market cap of $28.87 million, a PE ratio of -1.31 and a beta of -2.52. Femasys has a fifty-two week low of $0.86 and a fifty-two week high of $1.80.

Femasys (NASDAQ:FEMY) last issued its earnings results on Thursday, May 8th. The company reported ($0.23) EPS for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.06). Femasys had a negative net margin of 1,435.77% and a negative return on equity of 141.49%. Equities analysts anticipate that Femasys will post -0.86 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in FEMY. Dauntless Investment Group LLC acquired a new stake in Femasys during the 1st quarter worth about $1,969,000. Clear Creek Financial Management LLC grew its holdings in Femasys by 5.5% during the first quarter. Clear Creek Financial Management LLC now owns 270,371 shares of the company’s stock worth $338,000 after acquiring an additional 14,000 shares during the period. Citadel Advisors LLC acquired a new stake in Femasys during the fourth quarter worth about $45,000. Jane Street Group LLC acquired a new position in Femasys in the fourth quarter valued at approximately $30,000. Finally, Northern Trust Corp boosted its position in Femasys by 42.6% in the 4th quarter. Northern Trust Corp now owns 126,096 shares of the company’s stock worth $139,000 after purchasing an additional 37,675 shares in the last quarter. 65.27% of the stock is currently owned by institutional investors and hedge funds.

About Femasys

Femasys Inc, a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination.